Cargando…
Changes in allelic imbalances in locally advanced breast cancers after chemotherapy
In advanced breast cancers, TP53 mutation is highly predictive of complete response to high-dose epirubicin/cyclophosphamide chemotherapy. In these tumours with an altered control of genomic stability, accumulation of chemotherapy-induced genetic alterations may contribute to cell death and account...
Autores principales: | Varna, M, Soliman, H, Feugeas, J-P, Turpin, E, Chapelin, D, Legrès, L, Plassa, L-F, de Roquancourt, A, Espié, M, Misset, J-L, Janin, A, de Thé, H, Bertheau, P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360433/ https://www.ncbi.nlm.nih.gov/pubmed/17876337 http://dx.doi.org/10.1038/sj.bjc.6603937 |
Ejemplares similares
-
Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen
por: Bertheau, Philippe, et al.
Publicado: (2007) -
Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches
por: Lehmann-Che, J, et al.
Publicado: (2011) -
TP53 Status and Response to Treatment in Breast Cancers
por: Varna, Mariana, et al.
Publicado: (2011) -
Tracking sub-clonal TP53 mutated tumor cells in human metastatic renal cell carcinoma
por: Bousquet, Guilhem, et al.
Publicado: (2015) -
Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer
por: Bousquet, Guilhem, et al.
Publicado: (2017)